ATAI 주가 차트
ATAI 주가 예측
AtaiBeckley Inc
$4.33
-0.23%
$0
종가: Apr 28, 16:00:00 GMT-4
$4.35
0.46%
$0.01
애프터마켓: Apr 28, 20:00:00 GMT-4
뒤로
AtaiBeckley Inc (ATAI) 주가 예측
주요 통계
이전 종가
$4.34
시가
$4.3
일일 범위
$4.22 - $4.5
52주 범위
$1.29 - $6.75
거래량
3.2M
평균 거래량
5.1M
배당수익률
--
EPS(TTM)
-2.30
시가총액
$1.5B
ATAI란 무엇인가요?
Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York City, New York and currently employs 99 full-time employees. The company went IPO on 2021-06-18. The Company’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 (R-MDMA HCI) for social anxiety disorder. The firm is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. BPL-003 is a proprietary synthetic intranasal formulation of mebufotenin benzoate being developed as a potential treatment for people living with TRD. VLS-01 is a proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) being developed as a potential treatment for people living with TRD. EMP-01 is an oral formulation of R-MDMA, being developed as a potential treatment for people living with social anxiety disorder.